Postneoadjuvant treatment for triple-negative breast cancer.
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
pubmed:
23
8
2022
medline:
15
10
2022
entrez:
22
8
2022
Statut:
ppublish
Résumé
Triple-negative breast cancer (TNBC) has been conventionally associated with poor prognosis, as a result of limited therapeutic options. In the early setting, prognosis is informed by clinical-pathological factors; for patients receiving neoadjuvant treatments, pathological complete response (pCR) is the strongest factor. In this review, we mapped the landscape of clinical trials in the postneoadjuvant space, and identified three patterns of clinical trial design. For patients at higher risk, effective postneoadjuvant treatments are of paramount importance to address a high clinical need. Postneoadjuvant risk-adapted treatments have demonstrated to improve survival in patients at high of recurrence. Patients at high risk have indication for adjuvant treatment intensification, informed by baseline clinical, pathological or molecular factors (type 1 approach), on the presence, extent and molecular characteristics of the residual disease at the time of surgery (type 2) or on risk factors assessed in the postsurgical setting (type 3), for example, circulating tumour DNA. Most of the past trials were based on type 2 approaches, for example, with capecitabine and Olaparib. Few trials were based on a type 1 approach, notably pembrolizumab for early TNBC. The clinical validity of type 3 approaches is under investigation in several ongoing trials.
Identifiants
pubmed: 35993306
doi: 10.1097/CCO.0000000000000893
pii: 00001622-202211000-00005
doi:
Substances chimiques
Circulating Tumor DNA
0
Capecitabine
6804DJ8Z9U
Banques de données
ClinicalTrials.gov
['NCT01042379']
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
623-634Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Hennigs A, Riedel F, Gondos A, et al. Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. BMC Cancer 2016; 16:734.
Giuliano AE, Connolly JL, Edge SB, et al. Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67:290–303.
Marra A, Trapani D, Viale G, et al. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. NPJ breast cancer 2020; 6:54.
Ribelles N, Perez-Villa L, Jerez JM, et al. Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. Breast Cancer Res 2013; 15:R98.
Thomas A, Parsons HA, Smith KL. Late recurrence following early breast cancer. J Clin Oncol 2022; 40:1400–1406.
National Cancer Institute. surveillance epidemiology and end results (SEER) program. Breast cancer. Available at: https://seer.cancer.gov/statfacts/html/breast.html . [Accessed 17 May 2022]
Trapani D, Giugliano F, Uliano J, et al. Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review. Breast Cancer Res Treat 2021; 187:323–337.
Esserman LJ, Berry DA, DeMichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012; 30:3242–3249.
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384:164–172.
Conforti F, Pala L, Sala I, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ 2021; 375:e066381.
FDA (2012). Guidance for industry. Pathologic complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval. Available at: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInfo .
Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012; 366:2438–2441.
Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med 2020; 382:810–821.
Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol Off J Eur Soc Med Oncol 2022; 33:534–543.
Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 tria. Lancet 2020; 396:1090–1100.
Kennedy WR, Tricarico C, Gabani P, et al. Predictors of distant metastases in triple-negative breast cancer without pathologic complete response after neoadjuvant chemotherapy. J Natl Compr Canc Netw 2020; 18:288–296.
Shepherd JH, Ballman K, Polley M-YC, et al. CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer. J Clin Oncol 2022; 40:1323–1334.
Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007; 25:4414–4422.
Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol 2022; 23:149–160.
Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer. Ann Oncol 2021; 32:216–1235.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 2018; 19:27–39.
Mauri D, Pavlidis N, Ioannidis JPA. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005; 97:188–194.
Trapani D, Franzoi MA, Burstein HJ, et al. Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. Ann Oncol 2022; 33:702–712.
Locatelli MA, Curigliano G, Eniu A. Extended adjuvant chemotherapy in triple-negative breast cancer. Breast Care (Basel) 2017; 12:152–158.
Lluch A, Barrios CH, Torrecillas L, et al. GEICAM Spanish Breast Cancer Group, CIBOMA (Iberoamerican Coalition for Research in Breast Oncology), LACOG (Latin American Cooperative Oncology Group). Phase III trial of adjuvant capecitabine after standard neo-/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol 2020; 38:203.
Wang X, Wang S Sen, Huang H, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 Randomized Clinica. JAMA 2021; 325:50–58.
Parsons HA, Burstein HJ. Adjuvant capecitabine in triple-negative breast cancer: new strategies for tailoring treatment recommendations. JAMA 2021; 325:36–38.
Schmid P, Cortes J, Dent R, et al. KEYNOTE-522 Investigators. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 2022; 386:556–567.
Schmid P, Cortes J, Dent R, et al. VP7-2021: KEYNOTE-522: phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. Ann Oncol 2021; 32:1198–1200.
Pusztai L, Denkert C, O'Shaughnessy J, et al. Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. J Clin Oncol 2022; 40: (Suppl 16): [abstract 503].
Loibl S, Schneeweiss A, Huober J, et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Onc 2022; https://doi.org/10.1016/j.annonc.2022.07.1940
doi: 10.1016/j.annonc.2022.07.1940
Masuda N, Lee S-J, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017; 376:2147–2159.
Mayer IA, Zhao F, Arteaga CL, et al. Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131. J Clin Oncol 2021; 39:2539–2551.
Lehmann BD, Jovanović B, Chen X, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One 2016; 11:e0157368.
Saura C, Tseng L-M, Chan S, et al. Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker. Oncologist 2013; 18:787–794.
Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1 - or BRCA2 -mutated breast cancer. N Engl J Med 2021; 384:2394–2405.
Tutt ANJ, Garber J, Gelber RD, et al. VP1-2022: prespecified event driven analysis of overall survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer. Ann Oncol 2022; 33:566–568.
Filho OM, Stover DG, Asad S, et al. Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the brightness phase 3 randomized clinical trial. JAMA Oncol 2021; 7:603–608.
Guarneri V, Piacentini F, Ficarra G, et al. A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. Ann Oncol 2009; 20:1193–1198.
Jones RL, Salter J, A’Hern R, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009; 116:53–68.
Masuda H, Masuda N, Kodama Y, et al. Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients. Cancer Chemother Pharmacol 2011; 67:911–917.
Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 2015; 7:30ra133.
Balko JM, Giltnane JM, Wang K, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 2014; 4:232–245.
Wei B, Shan Y, Du Z, Yin C, et al. Identifying circulating tumor DNA mutations associated with neoadjuvant chemotherapy efficacy in local advanced breast cancer. Appl Biochem Biotechnol 2022; doi: 10.1007/s12010-022-03946-0.
doi: 10.1007/s12010-022-03946-0
Kim H, Kim YJ, Park D, et al. Dynamics of circulating tumor DNA during postoperative radiotherapy in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: a prospective observational study. Breast Cancer Res Treat 2021; 189:167–175.
Allouchery V, Perdrix A, Calbrix C, et al. Circulating PIK3CA mutation detection at diagnosis in nonmetastatic inflammatory breast cancer patients. Sci Rep 2021; 11:24041.
Silvestri M, Dugo M, Vismara M, et al. Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer. Sci Rep 2022; 12:1470.
Park YH, Lal S, Lee JE, et al. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nat Commun 2020 111 2020; 11:1–14.
Li X, Warren S, Pelekanou V, et al. Immune profiling of pre and posttreatment breast cancer tissues from the SWOG S0800 neoadjuvant trial. J Immunother Cancer 2019; 7:1–9.
Sarradin V, Lusque A, Filleron T, et al. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study. Breast Cancer Res 2021; 23:61.
Ladoire S, Arnould L, Apetoh L, et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 2008; 14:2413–2420.
Dieci MV, Criscitiello C, Goubar A, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol Off J Eur Soc Med Oncol 2014; 25:611–618.
Luen SJ, Salgado R, Dieci MV, et al. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Ann Oncol Off J Eur Soc Med Oncol 2019; 30:236–242.
Schneider BP, Jiang G, Ballinger TJ, et al. BRE12-158: a postneoadjuvant, randomized phase ii trial of personalized therapy versus treatment of physician's choice for patients with residual triple-negative breast cancer. J Clin Oncol 2022; 40:345–355.
André F, Bachelot T, Campone M, et al. Array CGH and DNA sequencing to personalize therapy for metastatic breast cancer: a prospective national trial (UNICANCER SAFIR-01). Ann Oncol 2012; 23 (9):Ixe6.
Crimini E, Repetto M, Aftimos P, et al. Precision medicine in breast cancer: from clinical trials to clinical practice. Cancer Treat Rev 2021; 98:102223.
Condorelli R, Mosele F, Verret B, et al. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol 2019; 30:365–373.
Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol 2018; 29:1895–1902.
Butler TM, Boniface CT, Johnson-Camacho K, et al. Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer. Cold Spring Harb Mol Case Stud 2019; 5:a003772.
McDonald BR, Contente-Cuomo T, Sammut SJ, et al. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Sci Transl Med 2019; 11:eaax7392.
Lipsyc-Sharf M, de Bruin EC, Santos K, et al. Circulating tumor DNA and late recurrence in high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. J Clin Oncol 2022; 40:2408–2419.
Cescon DW, Kalinsky K, DeMichele AM. Can a late interception by circulating tumor DNA deliver a win in estrogen receptor-positive early breast cancer? J Clin Oncol 2022; 40:2395–2397.
Magbanua MJM, Swigart LB, Wu HT, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol 2021; 32:229–239.
Papakonstantinou A, Gonzalez NS, Pimentel I, et al. Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: a systematic review and meta-analysis. Cancer Treat Rev 2022; 104:102362.
Garcia-Murillas I, Chopra N, Comino-Méndez I, et al. Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol 2019; 5:1473–1478.
Mendoza-Magbanua M, Brown Swigart L, Renner D, et al. Comparison of the predictive and prognostic significance of circulating tumor DNA in patients with high-risk HER2-negative breast cancer receiving neoadjuvant chemotherapy. #LB111 poster, AACR 2022.
D’Amico P, Corvaja C, Gerratana L, et al. The use of liquid biopsy in early breast cancer: clinical evidence and future perspectives. J Cancer Metastasis Treat 2021; 7:3.
Turner N, Swift C, Jenkins B, et al. Abstract GS3-06: primary results of the cTRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in patients with moderate and high risk early stage triple negative breast cancer. Cancer Res 2022; 82: (4 Suppl): GS3-06.
Parsons HA, Rhoades J, Reed SC, et al. Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer. Clin Cancer Res 2020; 26:2556–2564.
Gydush G, Nguyen E, Bae JH, et al. Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth. Nat Biomed Eng 2022; 6:257–266.